HEART-FAILURE - AN UPDATE ON PATHOPHYSIOLOGY

被引:0
|
作者
DREXLER, H
机构
关键词
HEART FAILURE; PATHOPHYSIOLOGY; PERIPHERAL ADAPTATION; ANGIOTENSIN-II;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocardial hypertrophy is an established risk factor for cardiovascular morbidity and mortality. Beyond quantitative and mechanical aspects hypertrophy is associated with alterations in cardiac gene expression, resulting in a more fetal-like myocyte phenotype with a fragile Ca++ homeostasis. Depressed expression of sarcoplasmatic reticulum ATPase is the hallmark of this overload phenotype. Conversely, the gene expression and the activity of sodium calcium exchanger is up-regulated in endstage heart failure. Both alterations contribute to prolonged cytosolic Ca++ transients, disturbed relaxation and, probably, to electrophysiologic instability. Angiotensin II is a growth promoting agent and several lines of circumferential evidence suggest that the local formation of angiotensin II might contribute to the trophic response and phenotype shift, in cardiac overload. The cardiac gene expression of angiotensin converting enzyme and angiotensinogen is increased early after cardiac overload and in patients with severe heart failure. Chronic ACE inhibition suppresses plasma and tissue ACE activity, reduces LV hypertrophy and improves long-term survival. The hallmark of the peripheral adaptation in chronic heart failure is systemic vasoconstriction, associated with neurohumoral activation. Several mechanisms are involved in the impaired peripheral perfusion, including increased sympathetic tone and increased vascular stiffness. Recently, data suggest an important role of the endothelium for perfusion of skeletal muscle in heart failure. Endothelium-dependent dilation of resistance vessels is blunted in patients with severe chronic heart failure. Conceivably, this abnormality may be involved in the impaired reactive hyperemia in patients with chronic heart failure. Moreover, alterations of skeletal muscle emerge in chronic heart failure contributing to reduced exercise performance. Both endothelial dysfunction and alterations of skeletal muscle appear to be reversible with chronic ACE-inhibitor therapy and/or physical training.
引用
收藏
页码:13 / 16
页数:4
相关论文
共 50 条
  • [31] FAILURE TO TREAT HEART-FAILURE
    不详
    LANCET, 1992, 339 (8788): : 278 - 279
  • [32] HYPOGLYCEMIA AND HEART-FAILURE
    DRAH, M
    GHOSE, RR
    POSTGRADUATE MEDICAL JOURNAL, 1992, 68 (798) : 304 - 304
  • [33] HOSPITALIZATION FOR HEART-FAILURE
    GHALI, JK
    COOPER, RS
    FORD, E
    ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (03) : 649 - &
  • [34] ECHOCARDIOGRAPHY AND HEART-FAILURE
    BARDERA, JCP
    MEDICINA CLINICA, 1990, 95 (17): : 653 - 655
  • [35] NIFEDIPINE IN HEART-FAILURE
    COREA, L
    BENTIVOGLIO, M
    VERDECCHIA, P
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1984, 36 (05): : 951 - 958
  • [36] CAPTOPRIL IN HEART-FAILURE
    CLELAND, JGF
    DARGIE, HJ
    HODSMAN, GP
    BALL, SG
    EAST, WB
    ROBERTSON, JIS
    BRITISH HEART JOURNAL, 1984, 51 (01): : 102 - 102
  • [37] CONGESTIVE HEART-FAILURE
    BERTEL, O
    THERAPEUTISCHE UMSCHAU, 1983, 40 (06) : 479 - 484
  • [38] DIDANOSINE AND HEART-FAILURE
    DEJONG, MD
    BORLEFFS, JCC
    LANCET, 1992, 339 (8796): : 806 - 807
  • [39] ANTIARRHYTHMICS IN HEART-FAILURE
    BRACHMANN, J
    SMITT, K
    BAYER, T
    WALDEKER, B
    HILBEL, T
    SWARTZER, M
    KUBLER, W
    KARDIOLOGIYA, 1992, 32 (04) : 38 - 40
  • [40] HYPOCALCEMIA AND HEART-FAILURE
    LIGORRA, C
    MONTANA, E
    SOLER, J
    GOMEZ, JM
    MEDICINA CLINICA, 1991, 96 (01): : 37 - 37